Screening for Patients with Mild Alzheimer Disease Using Frequency Doubling Technology Perimetry

• Published in: Neuro-ophthalmology (Amsterdam : Aeolus Press. 1980) Vol. 37; no. 6; pp. 239 - 246
• Main Authors: Aykan, Umit, Akdemir, M. Orcun, Yildirim, Ozlem, Varlibas, Figen
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare USA, Inc 01-12-2013; Taylor & Francis
• Subjects: Alzheimer disease; frequency doubling technology; magnocellular pathway; Original; visual field tests; magnocellular pathway; visual field tests; Alzheimer disease; frequency doubling technology
• ISSN: 0165-8107; 1744-506X
• DOI: 10.3109/01658107.2013.830627

Abstract
We compared the visual field performances of patients with mild Alzheimer disease (AD) with normal subjects and detected visual field impairment attributable to the magnocellular pathway using frequency doubling technology-Matrix (FDT-Matrix). We recruited 43 patients with mild AD (mean age: 68.0 ± 7.2 years) and 33 controls who are visually and cognitively normal (mean age: 64.1 ± 6.4 years). All participants had at least two reliable FDT-Matrix 30-2 tests. Reliability indices, global indices (mean deviation and pattern standard deviation), and glaucoma hemifield test results were measured with FDT-Matrix. The mean test duration was significantly longer in patient group compared with controls (p = 0.002). Among the reliability indices, false negatives were higher in patient group than controls (p = 0.003). There were statistically significant differences in mean deviation and pattern standard deviation values (p < 0.0001 and p < 0.0001, respectively) and glaucoma hemifield test results (p < 0.001) between the patient and the control group. Our results imply that the pathogenesis of cognitive deterioration may not only be confined to the cortical area but also to the magnocellular pathway. We underline that FDT testing can be useful for the identification of early impairment and the follow-up of patients with AD.